Compare MPLX LP (MPLX) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Moderna, Inc. — how do they compare? MPLX LP trades at $59.69 (market cap $60.12B), while Moderna, Inc. trades at $63.66 (market cap $24.18B). The key difference: MPLX LP is far larger — about 2.5× Moderna, Inc.'s market cap, and MPLX LP pays a 7.26% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MPLX | MRNA | |
|---|---|---|
Market Cap | $60.12B | $24.18B |
Sector | Technology | Health |
52-Week High | $60.51 | $81.80 |
52-Week Low | $47.80 | $22.36 |
Enterprise Value | $85.22B | $20.33B |
Dividend Yield | 7.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $59.75, up 1.79% today, with a bullish technical signal from moving averages and support near $59. The company reported strong 2025 results with $11.47B revenue and $4.91B net income, though Q1 and Q2 2026 EPS missed expectations. Recent news highlights a $2.25B senior notes offering (PRNewsWire, Aug 10, 2026) and solid Q2 performance driven by natural gas and NGL volume growth.
Outlook remains positive with a 67.86% analyst buy rating and $61.50 consensus price target, offering potential upside. Key opportunities include fee-based revenue stability and dividend growth, while risks involve higher capital spending and execution challenges on growth projects. The stock presents a balanced profile for income-focused investors.
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
